NO20006430L - Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner - Google Patents

Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner

Info

Publication number
NO20006430L
NO20006430L NO20006430A NO20006430A NO20006430L NO 20006430 L NO20006430 L NO 20006430L NO 20006430 A NO20006430 A NO 20006430A NO 20006430 A NO20006430 A NO 20006430A NO 20006430 L NO20006430 L NO 20006430L
Authority
NO
Norway
Prior art keywords
anxiety
nerve
depression
prevention
changes due
Prior art date
Application number
NO20006430A
Other languages
English (en)
Other versions
NO20006430D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20006430D0 publication Critical patent/NO20006430D0/no
Publication of NO20006430L publication Critical patent/NO20006430L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Det vises en sammensetning for forebygging og/eller terapeutisk behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjon som kan ta form av et kosttilskudd, koststøttemiddel eller av et egentlig legemiddel som innbefatter som kjennetegnende aktive bestanddeler acetyl L-karnitin og hypericin.
NO20006430A 1998-06-25 2000-12-15 Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner NO20006430L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000425A IT1299195B1 (it) 1998-06-25 1998-06-25 Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
PCT/IT1999/000175 WO1999066914A2 (en) 1998-06-25 1999-06-17 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin

Publications (2)

Publication Number Publication Date
NO20006430D0 NO20006430D0 (no) 2000-12-15
NO20006430L true NO20006430L (no) 2001-02-21

Family

ID=11406010

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20006430A NO20006430L (no) 1998-06-25 2000-12-15 Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner

Country Status (26)

Country Link
US (1) US6346282B1 (no)
EP (1) EP1089744B1 (no)
JP (1) JP2002518438A (no)
KR (1) KR20010053059A (no)
CN (1) CN1307479A (no)
AT (1) ATE228369T1 (no)
AU (1) AU756542B2 (no)
BR (1) BR9912179A (no)
CA (1) CA2334858C (no)
DE (1) DE69904173T2 (no)
DK (1) DK1089744T3 (no)
EE (1) EE200000729A (no)
ES (1) ES2188178T3 (no)
HU (1) HUP0102546A3 (no)
IL (1) IL140159A0 (no)
IS (1) IS5765A (no)
IT (1) IT1299195B1 (no)
MA (1) MA26651A1 (no)
NO (1) NO20006430L (no)
NZ (1) NZ508882A (no)
PL (1) PL194177B1 (no)
PT (1) PT1089744E (no)
SK (1) SK19302000A3 (no)
TN (1) TNSN99135A1 (no)
TR (1) TR200003736T2 (no)
WO (1) WO1999066914A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
DE10015617A1 (de) * 2000-03-29 2001-10-04 Peter Laetzsch Migränemittel
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
EP1854486A3 (de) * 2006-03-14 2010-06-02 Wilfried P. Bieger Verwendung von Neurotransmitter-Derivaten zur Herstellung von Mitteln zur Behandlung von neuroendokrinen gesundheitlichen Störungen
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
BRPI0900614A2 (pt) 2009-02-13 2011-06-28 Univ Fed Do Rio Grande Do Sul Ufrgs extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
PT2582368T (pt) * 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
JP2014145857A (ja) 2013-01-28 2014-08-14 Sony Corp 表示装置およびその製造方法、並びに電子機器
WO2016126169A1 (ru) * 2015-02-04 2016-08-11 Общество С Ограниченной Ответственностью "Консорциум-Пик" Способ повышения эффективности терапии антидепрессантом в комплексной антидепрессивной терапии и фармацевтическая комбинация

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE4239959A1 (de) * 1992-11-27 1994-06-01 Schwabe Willmar Gmbh & Co Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia

Also Published As

Publication number Publication date
CN1307479A (zh) 2001-08-08
US6346282B1 (en) 2002-02-12
IS5765A (is) 2000-12-08
PL345279A1 (en) 2001-12-03
ATE228369T1 (de) 2002-12-15
DE69904173D1 (de) 2003-01-09
IL140159A0 (en) 2002-02-10
SK19302000A3 (sk) 2001-09-11
BR9912179A (pt) 2001-04-10
TNSN99135A1 (fr) 2005-11-10
DE69904173T2 (de) 2003-08-28
AU756542B2 (en) 2003-01-16
EE200000729A (et) 2002-06-17
HUP0102546A2 (hu) 2001-10-28
DK1089744T3 (da) 2003-03-24
PL194177B1 (pl) 2007-05-31
ITRM980425A1 (it) 1999-12-25
AU4391099A (en) 2000-01-10
KR20010053059A (ko) 2001-06-25
EP1089744A2 (en) 2001-04-11
JP2002518438A (ja) 2002-06-25
WO1999066914A3 (en) 2000-04-06
IT1299195B1 (it) 2000-02-29
TR200003736T2 (tr) 2001-06-21
WO1999066914A2 (en) 1999-12-29
CA2334858C (en) 2010-08-24
NZ508882A (en) 2002-06-28
PT1089744E (pt) 2003-04-30
HUP0102546A3 (en) 2003-08-28
ES2188178T3 (es) 2003-06-16
MA26651A1 (fr) 2004-12-20
ITRM980425A0 (it) 1998-06-25
CA2334858A1 (en) 1999-12-29
NO20006430D0 (no) 2000-12-15
EP1089744B1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
NO20010954L (no) Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre
DK1331927T3 (da) Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
BR9611802A (pt) Composições farmacêuticas
NO20080284L (no) Cannabionoid aktiv farmasoytisk ingrediens for forbedrede doseringsformer
WO2008061226A3 (en) Sustained-release formulations of topiramate
TR200003735T2 (tr) Osteoporoz ve menopoz sendromuna bağlı rahatsızlıkların önlenmesi ve tedavileri
CY1107452T1 (el) Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων
KR940006578A (ko) 2-(3,4-디메톡신나모일) 아미노벤조산
IT1312377B1 (it) Composizioni a base di acido tiottico, cisteina e/o n-acetil cisteinada utilizzarsi in preparazioni farmaceutiche, dietetiche e cosmetiche
NO20035438L (no) Farmasoytisk formulering for effektiv administrering av apomorfin, 6aR-(-)-N-propyl-norapomorfin og deres derivater og prodrugs derav
UY27993A1 (es) Derivados de 4-pirrolidino-fenil-bencil eter
BR0314797A (pt) Derivados da pirimidineamida e o uso dos mesmos
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
JP2005511619A5 (no)
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
DZ3459A1 (fr) Derives de 2h-1-benzopyran, procedes de preparation de ces derniers et compositions pharmaceutiques dans lesquels ils entrent.
NO20022288L (no) Sammensetning til forebygging og/eller behandling av forstyrrelser forårsaket av abnorm lipid metabolisme, sominnbefatter propionyl L-karnitin og kitosan
WO2004030684A3 (en) Kavalactone product
NO20023117D0 (no) Sammensetning for forebygging og/eller behandling av lipidmetabolismeforstyrrelser og allergiske former
HUP0204180A2 (hu) Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application